Abstract | OBJECTIVE: METHODS: Economic analysis of a double-blind, randomized, clinical trial was used. Participants were randomly assigned to IGIV-C (N = 87) or IGIV-SD (N = 85) and monitored for the development of validated infections over the course of 9 months. Consumed resources were enumerated including cost of physician and emergency room visits, medications (prescription and over-the-counter), work productivity losses, and hospitalizations. Resource data was obtained from case report forms, patient diaries and the trial medication database. Because the amount of IGIV-SD used exceeded that of IGIV-C (nonstatistically significant difference) and the products are equivalently priced, we conservatively excluded investigational product acquisition cost to avoid artificially biasing incremental cost differences. We used a societal perspective with indirect costs, measured in 2003 US dollars. Pricing of both IGIV products is anticipated to be equivalent. RESULTS: In a multivariate analysis, annual mean per participant costs were significantly lower between those receiving IGIV-C compared with IGIV-SD for prescription medications [-US 302 dollars, 95% confidence interval (CI) -US 598 dollars to -US 6 dollars], hospitalization (-US 1454 dollars, 95% CI -US 1828 dollars to -US 1080 dollars) and total costs (-US 1304 dollars, 95% CI -US 1867 dollars to -US 742 dollars). Costs associated with lost work productivity and physician visits were similar in both groups (P > 0.10). In sensitivity analyses, varying costs of concomitant medications, hospitalization and outpatient care, did not significantly change our results. CONCLUSION: IGIV-C is cost-saving compared with IGIV-SD among persons with PIDD.
|
Authors | Parthiv J Mahadevia, John Strell, Dan Kunaprayoon, Erwin Gelfand |
Journal | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
(Value Health)
2005 Jul-Aug
Vol. 8
Issue 4
Pg. 488-94
ISSN: 1098-3015 [Print] United States |
PMID | 16091026
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Caprylates
- Immunoglobulins, Intravenous
|
Topics |
- Adult
- Canada
- Caprylates
- Chromatography
- Cost Savings
- Cost of Illness
- Drug Contamination
(economics, prevention & control)
- Female
- Humans
- Immunoglobulins, Intravenous
(adverse effects, economics)
- Immunologic Deficiency Syndromes
(drug therapy, economics)
- Likelihood Functions
- Male
- Models, Econometric
- Multivariate Analysis
- Randomized Controlled Trials as Topic
- Respiratory Tract Infections
(economics, prevention & control)
- Retrospective Studies
- Technology, Pharmaceutical
(economics)
- United States
|